Free Trial
NASDAQ:CRBU

Caribou Biosciences Q4 2024 Earnings Results & Report

Caribou Biosciences logo
$0.37 -0.01 (-1.63%)
As of 12:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Caribou Biosciences beat analyst earnings expectations but missed on revenue in its Q4 2024 results, released March 10, 2025. The company reported EPS of -$0.39 versus the -$0.40 consensus estimate, while revenue of $2.08 million fell short of the $2.11 million estimate by $29.00 thousand.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Caribou Biosciences EPS Results

Actual EPS
-$0.39
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Caribou Biosciences Revenue Results

Actual Revenue
$2.08 million
Expected Revenue
$2.11 million
Beat/Miss
Missed by -$29.00 thousand
YoY Revenue Growth
N/A

Earnings Documents

Caribou Biosciences Q4 2024 Earnings FAQ

Caribou Biosciences (NASDAQ:CRBU) reported earnings of -$0.39 per share for Q4 2024, beating the consensus estimate of -$0.40. The report was announced on Monday, March 10, 2025.

Caribou Biosciences reported revenue of $2.08 million for Q4 2024, against a consensus estimate of $2.11 million.

Caribou Biosciences Earnings Headlines

URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
See More Caribou Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Caribou Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Caribou Biosciences and other key companies, straight to your email.

About Caribou Biosciences

Caribou Biosciences (NASDAQ:CRBU) is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. Its work focuses on allogeneic, or donor-derived, CAR-T cell treatments designed to be manufactured for use by multiple patients.

The company uses its chRDNA genome-editing platform, which combines CRISPR RNA with DNA components, to make targeted changes to cells. Its clinical programs include CAR-T candidates directed at targets such as CD19 and BCMA, which are being developed for certain blood cancers.

Founded in 2011 and based in Berkeley, California, Caribou grew out of research into CRISPR genome-editing technology. Co-founder Rachel Haurwitz serves as the company’s president and chief executive officer.

View Caribou Biosciences Profile